Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.61 |
| ▸ | PRKDC | P78527 | 6/20 | 0.61 |
| ▸ | ABL1 | P00519 | 5/20 | 0.52 |
| ▸ | EGFR | P00533 | 5/20 | 0.52 |
| ▸ | SRC | P12931 | 5/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | MTOR | P42345 | 2/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.52 |
| ▸ | HCK | P08631 | 1/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.44 |
| ▸ | FGR | P09769 | 1/20 | 0.44 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.44 |
| ▸ | TXK | P42681 | 1/20 | 0.44 |
| ▸ | FRK | P42685 | 1/20 | 0.44 |
| ▸ | ABL2 | P42684 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30387156 | 0.85 | PIK3CD (0.59) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL20748491 | 0.83 | PIK3CG (0.54) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL30386858 | 0.83 | PIK3CD (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL10855 | 0.83 | MAP4K4 (0.49) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL16665784 | 0.82 | PIK3CD (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL11325 | 0.82 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL408618 | 0.82 | PIK3CD (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL23917237 | 0.81 | MAP2K4 (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL21467053 | 0.81 | PIK3CG (0.52) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL23917241 | 0.80 | PIK3CD (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230111917-A1 | KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| US-10028959-B2 | Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors | RESPIVERT LTD. (GB) | 2018-07-24 | — | — | US | disclosed |
| US-10028959-B2 | Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors | RESPIVERT LTD. (GB) | 2018-07-24 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| EP-2825202-B1 | STABILIZATION OF PHARMACEUTICAL COMPOSITIONS | RESPIVERT LTD (GB) | 2017-09-06 | — | — | EP | disclosed |
| EP-2825202-B1 | STABILIZATION OF PHARMACEUTICAL COMPOSITIONS | RESPIVERT LTD (GB) | 2017-09-06 | — | — | EP | disclosed |
| US-20170239256-A1 | CRYSTALLINE Pl3 KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| WO-2013136075-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | RESPIVERT LIMITED (GB) | 2013-09-19 | — | — | WO | disclosed |
| US-20130231355-A1 | QUINAZOLIN-4 (3H)- ONE DERIVATIVES USED AS P13 KINASE INHIBITORS | RESPIVERT LIMITED (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231355-A1 | QUINAZOLIN-4 (3H)- ONE DERIVATIVES USED AS P13 KINASE INHIBITORS | RESPIVERT LIMITED (US) | 2013-09-05 | — | — | US | disclosed |
| CN-101506211-B | Kinase antagonists | UNIV CALIFORNIA | 2013-05-22 | — | — | CN | disclosed |
| CN-102712645-A | Compound (I) | RESPIVERT LTD | 2012-10-03 | — | — | CN | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2012052753-A1 | QUINAZOLIN-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2012-04-26 | — | — | WO | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| CN-101506211-A | Kinase antagonists | UNIV CALIFORNIA (US) | 2009-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028959-B2 | Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors | MAP3K13, IRAK3, MAP3K3 | PIK3CG 171/4885PIK3CD 137/4885PIK3CA 85/4885 |
| US-20230111917-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | PIK3CG 30/4885PIK3CD 12/4885PIK3CA 4/4885 |
| US-20170239256-A1 | CRYSTALLINE Pl3 KINASE INHIBITORS | PLK3, PLK4, PLK2 | PIK3CG 260/4885PIK3CD 240/4885PIK3CA 209/4885 |
| US-20120208799-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CG 3708/4885PIK3CD 4224/4885PIK3CA 3148/4885 |
| US-20130231355-A1 | QUINAZOLIN-4 (3H)- ONE DERIVATIVES USED AS P13 KINASE INHIBITORS | MAP3K13, IRAK3, MAP3K3 | PIK3CG 171/4885PIK3CD 137/4885PIK3CA 85/4885 |
| US-20180118754-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CG 3708/4885PIK3CD 4224/4885PIK3CA 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.